Dovramilast
(Synonyms: CC-11050) 目录号 : GC67967Dovramilast (CC-11050) 是一种磷酸二酯酶 4 (PDE4) 抑制剂,具有口服活性,可以减少炎症反应,改善 Isoniazid 介导的肺部细菌清除。Dovramilast 作为辅助试剂,可用于结核病的研究。
Cas No.:340019-69-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB)[1].
Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology[2].
Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice[2].
Sampling time(h) | Concentration(ng/ml) | ||||
CC-11050 only | CC-11050+INH | ||||
1 | 1,331.6±136.97 | 905.35±594.23 | |||
2 | 1,409.47±140.85 | 1,309.39±214.08 | |||
5 | 948.85±128.7 | 1,609.18±167.2 | |||
8 | 820.6±265.98 | 1,271.73±249.18 | |||
24 | 1.27±1.1 | 4.96±1.85 | |||
Tmax(h) | 2.0 | 5.0 | |||
Cmax(ng/ml) | 1,410 | 1,610 | |||
AUClast(ng × h/ml) | 10,200 | 13,900 |
Animal Model: | B6D2F1 mice[2] |
Dosage: | 5, 25, or 50 mg/kg |
Administration: | oral, 5, 25, or 50 mg/kg, single |
Result: | Reduced PDE4 expression in mtb-infected mouse lungs. |
Animal Model: | B6D2F1 mice[2] |
Dosage: | 5, 25, or 50 mg/kg |
Administration: | oral gavage, 5, 25, or 50 mg/kg, single |
Result: | Improved antibiotic-mediated bacterial killing and reduced lung pathology. |
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.
[2]. Selvakumar Subbian, et al. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis. Front Immunol. 2016 Jun 17;7:238.
Cas No. | 340019-69-4 | SDF | Download SDF |
别名 | CC-11050 | ||
分子式 | C24H28N2O6S | 分子量 | 472.55 |
溶解度 | DMSO : 25 mg/mL (52.90 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | 4°C, away from moisture and light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1162 mL | 10.5809 mL | 21.1618 mL |
5 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL |
10 mM | 0.2116 mL | 1.0581 mL | 2.1162 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。